Clinical Trial Update: Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating melflufen in combination with daratumumab in relapsed or relapsed-refractory multiple myeloma was terminated; results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• Melflufen (melphalan flufenamide)

Snippet

Sponsor: Oncopeptides AB | Conditions: Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma | Phase 3 | Status: TERMINATED | Results posted: 2023-06-08